Short and long-term outcomes of angle supported phakic intraocular lens implantation in high myopic eyes

Saeed Al-Qahtani1, Khalid Al-Afraj2, Mohanna Al-Jindan2, Ali S Al-Beshri3, Rajiv Khandekar3

1Department of Surgery, Faculty of Medicine, Najran University, Najran 61441, Saudi Arabia
2Department of Ophthalmology, Dammam University, Dammam 34464, Saudi Arabia
3Research Department, King Khaled Eye Specialist Hospital, Riyadh 11462, Saudi Arabia

Correspondence to: Rajiv Khandekar. Research Department, King Khaled Eye Specialist Hospital, POB: 7191, Aruba Road, Riyadh 11462, Saudi Arabia. Rajiv.khandekar@gmail.com

Received: 2017-03-22       Accepted: 2018-03-01

Abstract
● This cohort study included 36 eyes of 21 patients with high myopia treated with angle supported phakic intraocular lens (pIOL). Endothelial cell density (ECD) at baseline, 6mo and 3y were 3017±296, 2775±265 and 2558±299 cells/mm² respectively. ECD loss at 6mo was 7.2% and annual ECD loss was 3% over 36mo. Corrected distance visual acuity at 36mo was 0.4 logMAR or better in 32 (88.9%) eyes. Intraocular pressure did not change (p=0.9). No eyes developed cataract, retinal detachment or pupillary distortion. Angle supported pIOL gives good visual outcome. Endothelial cell loss should be monitored.

KEYWORDS: phakic intraocular lens; high myopia; refractive surgery

DOI:10.18240/ijo.2018.05.27

Citation: Al-Qahtani S, Al-Afraj K, Al-Jindan M, Al-Beshri AS, Khandekar R. Short and long-term outcomes of angle supported phakic intraocular lens implantation in high myopic eyes. Int J Ophthalmol 2018;11(5):888-890

INTRODUCTION

Phakic intraocular lens (pIOL) is an alternative for excimer laser ablation in treatment of myopia. Unfortunately long-term damage to the corneal endothelium are noted. They are angle-supported pIOLs, iris fixated pIOLs and posterior chamber pIOLs. Outcomes of angle supported pIOL in an Arab population, are limited. We present short and long term outcomes of pIOL for high myopia in relation to the corneal status, intraocular pressure (IOP) and distance visual acuity after 6, 12, 24 and 36mo in Dhahran, Saudi Arabia.
RESULTS AND DISCUSSION

We studied 36 eyes of 21 patients. The median age was 27y (20-37y). The mean central corneal thickness (CCT) was 552±36 μm. The median spherical equivalent was -10.5 D (25% quartile -11 D). The mean K1 and K2 were 42.2±1.3 and 44.2±1.0 D respectively. The ECD at the different visits are presented in Table 1. There was acute loss of ECD in the 6mo following surgery and steady loss of ECD over the remaining period. An ECD loss of 33% is likely to occur 10y after angle supported pIOL implantation. The CDVA preoperatively and postoperatively is presented in Table 1. Eyes with preoperative CDVA of 0.11±0.08 logMAR improved to 0.4 logMAR or better in 32 (88.9%) eyes and 0.00 logMAR in 15 (41.7%) eyes after 36mo. The CDVA improved by two or more lines in 17 (47.2%) eyes. CDVA at 36mo improved by one line in another 15 (41.7%) eyes and remained the same in 4 (11.1%) eyes. The IOP preoperatively was 16.3±2.1 mm Hg. At 6, 12, 24 and 36mo follow-up, IOP was 16.1±1.9, 16.1±2.3, 15.5±1.5 and 16.1±2.0 mm Hg respectively. Change in IOP (P<0.9) was not significant. There were no cases of an oval pupil, pupillary block, cataract or retinal detachment. The correlation of CDVA to endothelial loss was not significant at 6mo (Spearman P=0.6), 12mo (P=0.3), 24mo (P=0.5) and 36mo (P=0.09). Correlation of CDVA to preoperative ECD (Spearman P=0.6), 12mo (P=0.2), 24mo (P=0.25), 36mo (P=0.17) was not significant. Visual outcomes after angle supported pIOL were promising, without increasing IOP but had slow progressive endothelial damage. Glaucoma, cataract, distortion of pupil and retinal detachment were not found. While reviewing the safety of pIOL, we noted that 8% acute ECD loss. This could be due to intraoperative manipulation and disturbances in hydrodynamics of aqueous humour in the anterior chamber. This was less than the 10% estimate as per ISO standard 11 979.8 Approximately a third of ECD is projected to be lost in a decade.

As the antenor chamber pIOLs is close to the cornea, cells have higher risk of damage.9 Excessive endothelial cell loss was reported for cachet and early anterior chamber pIOLs. Effect of pIOL implantation on ECD could be due to surgery also in addition to the physiologic decrease in ECD occurs with aging.9 ECD loss in different studies could be due to variations in study designs, tools and method used for endothelial cell counts.10 A clinical trial of anterior chamber angle-supported pIOL reported ECD losses from 4.2% to 15.3% after 3y.11 The 3-year decline in ECD in our study is lower than in studies using other types of pIOL.

The visual acuity at one year were similar to those of a European study.12 US Food and Drug Administration clinical trials of the Artisan/Verisyse iris-fixed pIOL reported CDVA of 20/20 in 31% of patients and 20/40 or better in 84% of patients after 3y.13 The viability, safety and complications of pIOLs implanted for such a long duration requires further study. Visual acuity improvement was likely due to the magnification effects. This could also be due to exclusion of patients with more than 2D astigmatism. There was no variation of IOP postoperatively. Kohnen et al9 reported transient increase in IOP over first 4wk. Angle supported pIOLs are less likely to obstruct the flow of aqueous.

There was no case of postoperative retinal detachment and lens changes. The risk of retinal detachment should be carefully assessed prior to pIOL surgery as high myopes are at higher risk of developing retinal detachments.9,10 Comprehensive retinal evaluation and prophylactic treatment of highly myopic eyes with retinal degeneration prior to pIOL implantation are recommended. Improvements in techniques over time have minimized the risk of lens opacity due to pIOL.

This was a one-armed cohort study, and comparison of outcomes with other types of pIOL should be judicious. Myopia is often associated with astigmatism, and we included patients with astigmatism of less than 2.00 D only. The implantation of angle supported pIOL resulted in promising outcomes for the correction of high myopia with mild astigmatism. However, chronic endothelial cell loss should be monitored.

ACKNOWLEDGEMENTS

Conflicts of Interest: Al-Qahtani S, None; Al-Afraj K, None; Al-Jindan M, None; Al-Beshri AS, None; Khandekar R, None.

REFERENCES

3 Huang D, Schallhorn SC, Sugar A, Farjo AA, Majmudar PA, Trattler WB, Tanzer DJ. Phakic intraocular lens implantation for the correction
Angle supported phakic IOL


